Literature DB >> 26810071

Updated TDP-43 in Alzheimer's disease staging scheme.

Keith A Josephs1,2, Melissa E Murray3, Jennifer L Whitwell4, Nirubol Tosakulwong5, Stephen D Weigand5, Leonard Petrucelli3, Amanda M Liesinger3, Ronald C Petersen6, Joseph E Parisi7, Dennis W Dickson3.   

Abstract

In this study, we update the TDP-43 in Alzheimer's disease staging scheme by assessing the topography of TDP-43 in 193 cases of Alzheimer's disease, in 14 different brain regions (eight previously described plus six newly reported) and use conditional probability to model the spread of TDP-43 across the 14 brain regions. We show that in addition to the eight original regions we previously reported [amygdala, entorhinal cortex, subiculum, dentate gyrus of the hippocampus, occipitotemporal cortex, inferior temporal cortex, middle frontal cortex and basal ganglia (putamen/globus pallidum)] that TDP-43 is also deposited in the insular cortex, ventral striatum, basal forebrain, substantia nigra, midbrain tectum, and the inferior olive of the medulla oblongata, in Alzheimer's disease. The conditional probability analysis produced six significantly different stages (P < 0.01), and suggests that TDP-43 deposition begins in the amygdala (stage 1), then moves to entorhinal cortex and subiculum (stage 2); to the dentate gyrus of the hippocampus and occipitotemporal cortex (stage 3); insular cortex, ventral striatum, basal forebrain and inferior temporal cortex (stage 4); substantia nigra, inferior olive and midbrain tectum (stage 5); and finally to basal ganglia and middle frontal cortex (stage 6). This updated staging scheme is superior to our previous staging scheme, classifying 100% of the cases (versus 94% in the old scheme), based on criteria provided, and shows clinical significance with some regions and with increasing stage. We discuss the relevance of the updated staging scheme, as well as its impact on the prion-like hypothesis of protein spread in neurodegenerative disease. We also address the issue of whether frontotemporal lobar degeneration with TDP-43 could be the primary pathology in stage 6.

Entities:  

Keywords:  Alzheimer’s disease; Brainstem; Insular cortex; Limbic; Staging; TDP-43

Mesh:

Substances:

Year:  2016        PMID: 26810071      PMCID: PMC5946692          DOI: 10.1007/s00401-016-1537-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  38 in total

Review 1.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nature       Date:  2013-09-05       Impact factor: 49.962

Review 2.  Cell-to-cell transmission of non-prion protein aggregates.

Authors:  Seung-Jae Lee; Paula Desplats; Christina Sigurdson; Igor Tsigelny; Eliezer Masliah
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 3.  The transcellular spread of cytosolic amyloids, prions, and prionoids.

Authors:  Adriano Aguzzi; Lawrence Rajendran
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

4.  Prion-like properties of pathological TDP-43 aggregates from diseased brains.

Authors:  Takashi Nonaka; Masami Masuda-Suzukake; Tetsuaki Arai; Yoko Hasegawa; Hiroyasu Akatsu; Tomokazu Obi; Mari Yoshida; Shigeo Murayama; David M A Mann; Haruhiko Akiyama; Masato Hasegawa
Journal:  Cell Rep       Date:  2013-07-03       Impact factor: 9.423

5.  Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease.

Authors:  Sukriti Nag; Lei Yu; Ana W Capuano; Robert S Wilson; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Ann Neurol       Date:  2015-04-22       Impact factor: 10.422

Review 6.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

7.  TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features.

Authors:  Keith A Josephs; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; Robert J Ivnik; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Ann Neurol       Date:  2015-09-16       Impact factor: 10.422

Review 8.  A critical reappraisal of current staging of Lewy-related pathology in human brain.

Authors:  Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2008-07-01       Impact factor: 17.088

9.  TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.

Authors:  Catalina Amador-Ortiz; Wen-Lang Lin; Zeshan Ahmed; David Personett; Peter Davies; Ranjan Duara; Neill R Graff-Radford; Michael L Hutton; Dennis W Dickson
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  126 in total

1.  Expression profiling of precuneus layer III cathepsin D-immunopositive pyramidal neurons in mild cognitive impairment and Alzheimer's disease: Evidence for neuronal signaling vulnerability.

Authors:  Bin He; Sylvia E Perez; Sang H Lee; Stephen D Ginsberg; Michael Malek-Ahmadi; Elliott J Mufson
Journal:  J Comp Neurol       Date:  2020-05-05       Impact factor: 3.215

2.  Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons.

Authors:  Jozsef Gal; Jing Chen; Yuriko Katsumata; David W Fardo; Wang-Xia Wang; Sergey Artiushin; Douglas Price; Sonya Anderson; Ela Patel; Haining Zhu; Peter T Nelson
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

3.  Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center.

Authors:  Teresa Jenica Filshtein; Brittany N Dugger; Lee-Way Jin; John M Olichney; Sarah T Farias; Luis Carvajal-Carmona; Paul Lott; Dan Mungas; Bruce Reed; Laurel A Beckett; Charles DeCarli
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

4.  The influence of tau, amyloid, alpha-synuclein, TDP-43, and vascular pathology in clinically normal elderly individuals.

Authors:  Alexandra M Wennberg; Jennifer L Whitwell; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Mary M Machulda; Leonard Petrucelli; Michelle M Mielke; Clifford R Jack; David S Knopman; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2019-01-21       Impact factor: 4.673

5.  The role of liquid-liquid phase separation in aggregation of the TDP-43 low-complexity domain.

Authors:  W Michael Babinchak; Raza Haider; Benjamin K Dumm; Prottusha Sarkar; Krystyna Surewicz; Jin-Kyu Choi; Witold K Surewicz
Journal:  J Biol Chem       Date:  2019-02-27       Impact factor: 5.157

Review 6.  Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain.

Authors:  Richard A Hickman; Xena E Flowers; Thomas Wisniewski
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 5.081

7.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

8.  Brain atrophy in primary age-related tauopathy is linked to transactive response DNA-binding protein of 43 kDa.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; David S Knopman; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-05-02       Impact factor: 21.566

9.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

10.  In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.

Authors:  Veronika Hanko; Alexandra C Apple; Kathryn I Alpert; Kristen N Warren; Julie A Schneider; Konstantinos Arfanakis; David A Bennett; Lei Wang
Journal:  Neurobiol Aging       Date:  2018-10-25       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.